SCYX has been successfully added to your Stock Email Alerts list.
You can manage your stock email alerts here.
SCYX has been removed from your Stock Email Alerts list.
Please enter Portfolio Name for new portfolio.
SCYNEXIS's total inventories for the quarter that ended in Mar. 2024 was $0.0 Mil. SCYNEXIS's average total inventories from the quarter that ended in Dec. 2023 to the quarter that ended in Mar. 2024 was $0.0 Mil.
In Ben Graham's calculation of Net-Net Working Capital, inventory is only considered worth half of its book value. SCYNEXIS's Net-Net Working Capital per share for the quarter that ended in Mar. 2024 was $0.96.
Days Inventory indicates the number of days of goods in sales that a company has in the inventory.
Inventory Turnover measures how fast the company turns over its inventory within a year.
Inventory-to-Revenue determines the ability of a company to manage their inventory levels. It measures the percentage of Inventories the company currently has on hand to support the current amount of Revenue. SCYNEXIS's Inventory-to-Revenue for the quarter that ended in Mar. 2024 was 0.00.
The historical data trend for SCYNEXIS's Total Inventories can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
SCYNEXIS Annual Data | |||||||||||||||||||||
Trend | Dec14 | Dec15 | Dec16 | Dec17 | Dec18 | Dec19 | Dec20 | Dec21 | Dec22 | Dec23 | |||||||||||
Total Inventories | Get a 7-Day Free Trial | - | - | 0.46 | 0.90 | - |
SCYNEXIS Quarterly Data | ||||||||||||||||||||
Jun19 | Sep19 | Dec19 | Mar20 | Jun20 | Sep20 | Dec20 | Mar21 | Jun21 | Sep21 | Dec21 | Mar22 | Jun22 | Sep22 | Dec22 | Mar23 | Jun23 | Sep23 | Dec23 | Mar24 | |
Total Inventories | Get a 7-Day Free Trial | 1.11 | 10.29 | 13.11 | - | - |
Total Inventories includes the raw materials, work-in-process goods and completely finished goods of a company. It is a portion of a company's current assets.
SCYNEXIS (NAS:SCYX) Total Inventories Explanation
Inventory control is an important part of business operation. If a company does not have enough inventory, it may not be able to meet customers' required delivery time. If it has too much inventory, the cost of holding the inventory can be high.
1. In Ben Graham's calculation of Net-Net Working Capital (NNWC), inventory is only considered worth half of its book value.
SCYNEXIS's Net-Net Working Capital Per Share for the quarter that ended in Mar. 2024 is
Net-Net Working Capital Per Share (Q: Mar. 2024 ) | |||||||
= | (Cash And Cash Equivalents | + | 0.75 * Accounts Receivable | + | 0.5 * Total Inventories | - | Total Liabilities |
- | Preferred Stock | - | Minority Interest) | / | Shares Outstanding (EOP) | ||
= | (80.244 | + | 0.75 * 0 | + | 0.5 * 0 | - | 44.149 |
- | 0 | - | 0) | / | 37.7798 | ||
= | 0.96 |
2. Days Inventory indicates the number of days of goods in sales that a company has in the inventory.
SCYNEXIS's Days Inventory for the three months ended in Mar. 2024 is calculated as:
Days Inventory | = | Average Total Inventories (Q: Mar. 2024 ) | / | Cost of Goods Sold (Q: Mar. 2024 ) | * | Days in Period |
= | 0 | / | 0 | * | 365 / 4 | |
= |
3. Inventory Turnover measures how fast the company turns over its inventory within a year.
SCYNEXIS's Inventory Turnover for the quarter that ended in Mar. 2024 is calculated as
Inventory Turnover | = | Cost of Goods Sold (Q: Mar. 2024 ) | / | Average Total Inventories (Q: Mar. 2024 ) |
= | 0 | / | 0 | |
= | N/A |
4. Inventory-to-Revenue determines the ability of a company to manage their inventory levels. It measures the percentage of Inventories the company currently has on hand to support the current amount of Revenue.
SCYNEXIS's Inventory to Revenue for the quarter that ended in Mar. 2024 is calculated as
Inventory-to-Revenue | = | Average Total Inventories (Q: Mar. 2024 ) | / | Revenue (Q: Mar. 2024 ) |
= | 0 | / | 1.373 | |
= | 0.00 |
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Be Aware
Manufacturers with durable competitive advantages have the advantage that the products they sell do not change, and therefore will never become obsolete. Buffett likes this advantage.
When identifying manufacturers with durable competitive advantage, look for inventory and net earnings that rise correspondingly. This indicates that the company is finding profitable ways to increase sales which called for an increase in inventory.
Manufacturers with inventories that spike up and down are indicative of competitive industries subject to boom and bust.
Thank you for viewing the detailed overview of SCYNEXIS's Total Inventories provided by GuruFocus.com. Please click on the following links to see related term pages.
David C Hastings | director | C/O ARBUTUS BIOPHARMA, 100-8900 GLENLYON PARKWAY, BURNABY A1 V5J 5J8 |
Brian Philippe Tinmouth | director | 1 EVERTRUST PLAZA, 13TH FLOOR, JERSEY CITY NJ 07302-6548 |
Guy Macdonald | director | C/O IDENIX PHARMACEUTICALS, INC., 60 HAMPSHIRE STREET, CAMBRIDGE MA 02139 |
Ann Hanham | director | ONE EMBRACADERO CTR, STE 2700, SAN FRANCISCO CA 94111 |
Steven C Gilman | director | 110 HARTWELL AVENUE, LEXINGTON MA 02421 |
Armando Anido | director | 80 W. LANCASTER AVENUE, SUITE 300, DEVON PA 19333 |
Ivor Macleod | officer: Chief Financial Officer | 3201 CARNEGIE AVENUE, CLEVELAND OH 44115-2634 |
Scott Sukenick | officer: General Counsel | 101 HUDSON STREET, SUITE 3610, JERSEY CITY NJ 07302 |
Marco Taglietti | director | C/O FOREST LABORATORIES, INC., 909 THIRD AVENUE, NEW YORK NY 10022 |
Lawrence R Hoffman | officer: Interim CFO | C/O COVALENT GROUP, INC., 1275 DRUMMERS LANE, SUITE 100, WAYNE PA 19087 |
Christine Coyne | officer: Chief Commercial Officer | 1 EVERTRUST PLAZA, 13TH FLOOR, JERSEY CITY NJ 07302-6548 |
Perceptive Life Sciences Master Fund Ltd | 10 percent owner | C/O PERCEPTIVE ADVISORS LLC, 51 ASTOR PLACE, 10TH FLOOR, NEW YORK NY 10003 |
Joseph Edelman | 10 percent owner | C/O PERCEPTIVE ADVISORS LLC, 51 ASTOR PLACE, 10TH FLOOR, NEW YORK NY 10003 |
Eric Francois | officer: Chief Financial Officer | C/O SCYNEXIS, INC., 3501 C TRICENTER BOULEVARD, DURHAM NC 27713 |
Gonzalez David Angulo | officer: Chief Medical Officer | C/O SCYNEXIS, INC., 3501 C TRICENTER BOULEVARD, DURHAM NC 27713 |
From GuruFocus
By Business Wire • 11-15-2023
By PRNewswire • 11-15-2023
By PRNewswire • 11-14-2023
By PRNewswire • 12-28-2023
By PRNewswire • 12-20-2023
By PRNewswire • 01-03-2024
By PRNewswire • 11-19-2023
By ACCESSWIRE • 11-28-2023
By PRNewswire • 12-29-2023
By PRNewswire • 01-06-2024
Disclaimers: GuruFocus.com is not operated by a broker or a dealer. It has an affiliated registered investment adviser, which serves as the subadviser to an exchange traded fund. This investment adviser does not provide advice to individual investors. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes provided by InterActive Data. Fundamental company data provided by Morningstar, updated daily.